Overview

HypoPet is a Swiss biotech company engaged in the research, development, manufacture and licensing of therapeutic vaccines for major unmet needs in companion animal medicine; allergy, inflammation, pain, cardiovascular and metabolic disease and cancer. HypoPet has developed and patented a recombinant virus-like particle vaccine platform, which can be used to induce long-lived antibodies that specifically target key molecules that drive chronic diseases. With our technology we aim to leverage the profound success achieved with human monoclonal antibodies into cost-effective treatments for pets.